Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan.

MLA

Abu Hejleh, Taher, et al. “Beyond Clinical Trials: Real-World Impact of Immunotherapy on NSCLC in Jordan.” Frontiers in Oncology, vol. 14, Apr. 2024, p. 1369126. EBSCOhost, https://doi.org/10.3389/fonc.2024.1369126.

APA

Abu Hejleh, T., AlSawalha, K., Abdel Hafiz, S., Al-Batsh, T., Abu Hejleh, R., Yaser, S., Abu Jazar, H., Khader, J., Alnsour, A., Mohamad, I., Abdel Jalil, R., Abu-Shanab, A., Gharaibeh, A., Abu Shattal, M., Alibraheem, A., Haddad, H., Mahmoud, N., Obeidat, S., Al-Jaghbeer, M. J., … Al-Rabi, K. (2024). Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan. Frontiers in Oncology, 14, 1369126. https://doi.org/10.3389/fonc.2024.1369126

Chicago

Abu Hejleh, Taher, Karim AlSawalha, Sufian Abdel Hafiz, Tamer Al-Batsh, Roaa Abu Hejleh, Sameer Yaser, Husam Abu Jazar, et al. 2024. “Beyond Clinical Trials: Real-World Impact of Immunotherapy on NSCLC in Jordan.” Frontiers in Oncology 14 (April): 1369126. doi:10.3389/fonc.2024.1369126.